Tyra Biosciences, Inc. 8K

Tyra Biosciences reported Q1 2026 results, advanced three Phase 2 dabogratinib programs, added a new board member, raised $147.9 million via an ATM equity offering, and projected cash runway into 2H 2028.

On May 13, 2026, Tyra Biosciences, Inc. reported its financial results for the quarter ended March 31, 2026 and provided a business update, highlighting advancement of its “dabogratinib 3x3” strategy across three Phase 2 programs (SURF303 in LG-UTUC with first patient dosed and initial data expected in 2027, SURF302 in IR NMIBC with initial three‑month complete response data expected in August 2026, and BEACH301 in achondroplasia with the fourth dose level cleared and initial safety sentinel cohort data expected in Q4 2026), presentation of new clinical and preclinical data at major medical meetings, the appointment of industry veteran Habib Dable to its board of directors, and a strengthened balance sheet following $147.9 million of net proceeds from at‑the‑market equity issuance, resulting in cash, cash equivalents and marketable securities of $383.5 million and an estimated cash runway into the second half of 2028, alongside disclosure of increased R&D and G&A expenses and a net loss of $39.3 million for the quarter.

Filing Facts

CIK

1863127

Ticker

TYRA

Form

8K

Source Type

fda

Accession

0001193125-26-220638

Alert Tier

6